Who are Daunorubicin Hydrochloride's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Treanda, Zolinza, Feximac, Ellence, Idamycin Pfs, Idamycin Pfs.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/daunorubicin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Daunorubicin Hydrochloride — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Daunorubicin Hydrochloride (daunorubicin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anthracycline Topoisomerase Inhibitor. Area: Oncology.

marketed Anthracycline Topoisomerase Inhibitor Histone deacetylase 6 Oncology Live · refreshed every 30 min

Target snapshot

Daunorubicin Hydrochloride (daunorubicin) — Meiji Seika Pharma Co., Ltd.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Daunorubicin Hydrochloride TARGET	daunorubicin	Meiji Seika Pharma Co., Ltd	marketed	Anthracycline Topoisomerase Inhibitor	Histone deacetylase 6	1979-01-01
Treanda	BENDAMUSTINE	Baxter	marketed	Alkylating Drug	Histone deacetylase 6	2008-01-01
Zolinza	VORINOSTAT	Merck & Co.	marketed	Histone Deacetylase Inhibitor [EPC]	Histone deacetylase 6	2006-01-01
Feximac	BUFEXAMAC		marketed	bufexamac	Histone deacetylase 10, Histone deacetylase 6, Arachidonate 5-lipoxygenase
Ellence	EPIRUBICIN	Pfizer	marketed	Anthracycline Topoisomerase Inhibitor	Tyrosine-protein kinase Fyn	1999-01-01
Idamycin Pfs	Idarubicin Hydrochloride	Pfizer Inc.	marketed	Anthracycline topoisomerase inhibitor	DNA, Topoisomerase II	1990-01-01
Idamycin Pfs	IDARUBICIN HYDROCHLORIDE		marketed	Anthracycline Topoisomerase Inhibitor	DNA, topoisomerase II	1990-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anthracycline Topoisomerase Inhibitor class)

· 2 drugs in this class
Pfizer · 2 drugs in this class
Meiji Seika Pharma Co., Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Daunorubicin Hydrochloride — Competitive Intelligence Brief. https://druglandscape.com/ci/daunorubicin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing